Skip to main content
NCBI home page
Mediators of Inflammation logoLink to Mediators of Inflammation
. 2001 Dec;10(6):323–332. doi: 10.1080/09629350120102343

Influence of a macrolide antibiotic, roxithromycin, on mast cell growth and activation in vitro.

T Shimane 1, K Asano 1, M Suzuki 1, T Hisamitsu 1, H Suzaki 1
PMCID: PMC1781731  PMID: 11817673

Abstract

BACKGROUND: Long-term administration of macrolide antibiotics is recognized to be able to favorably modify the clinical condition of inflammatory diseases, such as diffuse panbronchiolitis and cystic fibrosis. However, the precise mechanisms by which macrolide antibiotics could improve clinical conditions of the patients are not well understood. AIM: The present study was designed to examine the influence of macrolide antibiotics on effector cell functions responsible for inflammation through the choice of roxithromycin (RXM) and mast cell. METHODS: Mast cells were induced by long-term culture of splenocytes from BALB/c mice. RXM was added to the cultures at seeding and then every 4-5 days, when the culture medium was replaced with a fresh one. The influence of RXM on mast cell growth was evaluated by counting the number of cells grown on the 16th day. We also examined the influence of RXM on mast cell activation by examining histamine release and inflammatory cytokine secretion. RESULTS AND CONCLUSION: RXM could not inhibit mast cell growth, even when splenocytes were exposed to 100 microg/ml of RXM throughout the entire culture periods. RXM also could not suppress histamine release from cultured mast cells in response to non-immunological and immunological stimulations. However, RXM could suppress inflammatory cytokine, interleukin-1beta, interleukin-6, granulocyte macrophage-colony stimulating factor and tumor necrosis factor-alpha, secretions induced by concanavalin A stimulation at a concentration of as little as 0.5 microg/ml. These results may suggest that RXM modulated the ability of mast cells to secrete inflammatory cytokines and results in improvement of clinical condition of chronic inflammatory diseases.

Full Text

The Full Text of this article is available as a PDF (248.3 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Altschuler E. L. Azithromycin, the multidrug-resistant protein, and cystic fibrosis. Lancet. 1998 Apr 25;351(9111):1286–1286. doi: 10.1016/S0140-6736(05)79350-8. [DOI] [PubMed] [Google Scholar]
  2. Ashman R. I., Jarboe D. L., Conrad D. H., Huff T. F. The mast cell-committed progenitor. In vitro generation of committed progenitors from bone marrow. J Immunol. 1991 Jan 1;146(1):211–216. [PubMed] [Google Scholar]
  3. Bradding P. Human mast cell cytokines. Clin Exp Allergy. 1996 Jan;26(1):13–19. doi: 10.1111/j.1365-2222.1996.tb00051.x. [DOI] [PubMed] [Google Scholar]
  4. Depoortere I., Peeters T. L. Transduction mechanism of motilin and motilides in rabbit duodenal smooth muscle. Regul Pept. 1995 Feb 14;55(3):227–235. doi: 10.1016/0167-0115(94)00111-a. [DOI] [PubMed] [Google Scholar]
  5. Desaki M., Takizawa H., Ohtoshi T., Kasama T., Kobayashi K., Sunazuka T., Omura S., Yamamoto K., Ito K. Erythromycin suppresses nuclear factor-kappaB and activator protein-1 activation in human bronchial epithelial cells. Biochem Biophys Res Commun. 2000 Jan 7;267(1):124–128. doi: 10.1006/bbrc.1999.1917. [DOI] [PubMed] [Google Scholar]
  6. Endres S., Fülle H. J., Sinha B., Stoll D., Dinarello C. A., Gerzer R., Weber P. C. Cyclic nucleotides differentially regulate the synthesis of tumour necrosis factor-alpha and interleukin-1 beta by human mononuclear cells. Immunology. 1991 Jan;72(1):56–60. [PMC free article] [PubMed] [Google Scholar]
  7. Ennis M., Truneh A., White J. R., Pearce F. L. Inhibition of histamine secretion from mast cells. Nature. 1981 Jan 15;289(5794):186–187. doi: 10.1038/289186a0. [DOI] [PubMed] [Google Scholar]
  8. Eyraud A., Descotes J., Lombard J. Y., Laschi-Loquerie A., Tachon P., Veysseyre C., Evreux J. C. Effects of erythromycin, josamycin and spiramycin on rat polymorphonuclear leukocyte chemotaxis. Chemotherapy. 1986;32(4):379–382. doi: 10.1159/000238438. [DOI] [PubMed] [Google Scholar]
  9. Gilbert H. S., Ornstein L. Basophil counting with a new staining method using alcian blue. Blood. 1975 Aug;46(2):279–286. [PubMed] [Google Scholar]
  10. Gordon J. R., Galli S. J. Mast cells as a source of both preformed and immunologically inducible TNF-alpha/cachectin. Nature. 1990 Jul 19;346(6281):274–276. doi: 10.1038/346274a0. [DOI] [PubMed] [Google Scholar]
  11. Hatfield S. M., Roehm N. W. Cyclosporine and FK506 inhibition of murine mast cell cytokine production. J Pharmacol Exp Ther. 1992 Feb;260(2):680–688. [PubMed] [Google Scholar]
  12. Holtzman M. J., Fabbri L. M., O'Byrne P. M., Gold B. D., Aizawa H., Walters E. H., Alpert S. E., Nadel J. A. Importance of airway inflammation for hyperresponsiveness induced by ozone. Am Rev Respir Dis. 1983 Jun;127(6):686–690. doi: 10.1164/arrd.1983.127.6.686. [DOI] [PubMed] [Google Scholar]
  13. Iino Y., Toriyama M., Kudo K., Natori Y., Yuo A. Erythromycin inhibition of lipopolysaccharide-stimulated tumor necrosis factor alpha production by human monocytes in vitro. Ann Otol Rhinol Laryngol Suppl. 1992 Oct;157:16–20. doi: 10.1177/0003489492101s1005. [DOI] [PubMed] [Google Scholar]
  14. Jaffé A., Francis J., Rosenthal M., Bush A. Long-term azithromycin may improve lung function in children with cystic fibrosis. Lancet. 1998 Feb 7;351(9100):420–420. doi: 10.1016/S0140-6736(05)78360-4. [DOI] [PubMed] [Google Scholar]
  15. Kay A. B. Asthma and inflammation. J Allergy Clin Immunol. 1991 May;87(5):893–910. doi: 10.1016/0091-6749(91)90408-g. [DOI] [PubMed] [Google Scholar]
  16. Kinet J. P. The high-affinity receptor for IgE. Curr Opin Immunol. 1989;2(4):499–505. doi: 10.1016/0952-7915(90)90002-x. [DOI] [PubMed] [Google Scholar]
  17. Konno S., Asano K., Kurokawa M., Ikeda K., Okamoto K., Adachi M. Antiasthmatic activity of a macrolide antibiotic, roxithromycin: analysis of possible mechanisms in vitro and in vivo. Int Arch Allergy Immunol. 1994 Nov;105(3):308–316. doi: 10.1159/000236773. [DOI] [PubMed] [Google Scholar]
  18. Miyachi Y., Yoshioka A., Imamura S., Niwa Y. Effect of antibiotics on the generation of reactive oxygen species. J Invest Dermatol. 1986 Apr;86(4):449–453. doi: 10.1111/1523-1747.ep12285793. [DOI] [PubMed] [Google Scholar]
  19. Miyatake H., Suzuki K., Taki F., Takagi K., Satake T. Effect of erythromycin on bronchial hyperresponsiveness in patients with bronchial asthma. Arzneimittelforschung. 1991 May;41(5):552–556. [PubMed] [Google Scholar]
  20. Miyatake H., Taki F., Taniguchi H., Suzuki R., Takagi K., Satake T. Erythromycin reduces the severity of bronchial hyperresponsiveness in asthma. Chest. 1991 Mar;99(3):670–673. doi: 10.1378/chest.99.3.670. [DOI] [PubMed] [Google Scholar]
  21. Nadel J. A. Inflammation and asthma. J Allergy Clin Immunol. 1984 May;73(5 Pt 2):651–653. doi: 10.1016/0091-6749(84)90299-9. [DOI] [PubMed] [Google Scholar]
  22. Shimozato T., Iwata M., Kawada H., Tamura N. Human immunoglobulin preparation for intravenous use induces elevation of cellular cyclic adenosine 3':5'-monophosphate levels, resulting in suppression of tumour necrosis factor alpha and interleukin-1 production. Immunology. 1991 Apr;72(4):497–501. [PMC free article] [PubMed] [Google Scholar]
  23. Suzaki H., Asano K., Ohki S., Kanai K., Mizutani T., Hisamitsu T. Suppressive activity of a macrolide antibiotic, roxithromycin, on pro-inflammatory cytokine production in vitro and in vivo. Mediators Inflamm. 1999;8(4-5):199–204. doi: 10.1080/09629359990351. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Takizawa H., Desaki M., Ohtoshi T., Kawasaki S., Kohyama T., Sato M., Tanaka M., Kasama T., Kobayashi K., Nakajima J. Erythromycin modulates IL-8 expression in normal and inflamed human bronchial epithelial cells. Am J Respir Crit Care Med. 1997 Jul;156(1):266–271. doi: 10.1164/ajrccm.156.1.9612065. [DOI] [PubMed] [Google Scholar]
  25. Wershil B. K., Furuta G. T., Lavigne J. A., Choudhury A. R., Wang Z. S., Galli S. J. Dexamethasone or cyclosporin A suppress mast cell-leukocyte cytokine cascades. Multiple mechanisms of inhibition of IgE- and mast cell-dependent cutaneous inflammation in the mouse. J Immunol. 1995 Feb 1;154(3):1391–1398. [PubMed] [Google Scholar]

Articles from Mediators of Inflammation are provided here courtesy of Wiley

RESOURCES